TABLE 3.
Effect of prototype anti‐inflammatory compounds on seizure burden in the Theiler's murine encephalomyelitis virus (TMEV) model against handling‐induced seizures
| Compound | Mechanism of action | Dose mg/kg, IP |
% VEH Cumulative seizure burden |
Protection (# Protected/# Tested) |
|---|---|---|---|---|
| Diclofenac | NSAID | 5 | 74.2 ± 17.1 | 8/20 |
| 10 | 74.6 ± 19.8 | 10/20 | ||
| Ibuprofen | NSAID | 10 | 110 ± 14.0 | 2/20 |
| 50 | 60.8 ± 12.8 | 7/20 | ||
| Celecoxib | Cox‐2 inhibitor | 5 | 69.5 ± 9.1* | 2/20 |
| 10 | 73.7 ± 8.6* | 1/20 | ||
| Dexamethasone | Corticosteroid | 20 | 38.3 ± 6.1**** | 4/20 |
| Prednisone | Corticosteroid | 5 | 91.8 ± 15.0 | 4/20 |
| 10 | 108 + 15.5 | 3/20 | ||
| 20 a | 68.3 ± 8.2* | 2/20 | ||
| Minocycline | Unknown | 50 a | 58.0 ± 14.2 | 6/19 |
*P < .05, ****P < .0001 compared to VEH seizure burden from the same testing cohort; Mann‐Whitney U test.
a
Compound was administered once daily (QD), whereas other compounds noted were administered twice daily (BID).